Head-to-head evidence
SAL0150 vs semaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
SAL0150
Developed by Shenzhen Salubris Pharmaceuticals
NCT05782192 · Phase 3 · completed
The study was randomized, quadruple-masked, and included both active and placebo comparator groups, with 458 participants. Its primary endpoint was the surrogate measure of HbA1c change. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT07570810 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SAL0150's landscape · semaglutide's landscape